News >

Shifting NSCLC Landscape Creates Confusion for PD-1/Chemo Combo

Angelica Welch
Published: Tuesday, Apr 10, 2018

Ari VanderWalde, MD

Ari VanderWalde, MD
The rationale behind combining chemotherapy with immunotherapy in non–small cell lung cancer (NSCLC) is perplexing to Ari VanderWalde, MD, as he says findings from 2 pivotal trials in the last year—KEYNOTE-021 and IMpower150—may not be fully applicable to the current landscape.

VanderWalde, director of clinical research at West Cancer Center, associate vice chancellor of clinical research at the University of Tennessee Health Science Center, explained his trepidation with these combinations of chemotherapy and immunotherapy in an interview during the meeting.

OncLive: Can you provide an overview of your presentation?

VanderWalde: Combining immunotherapy with other immunotherapy, or with chemotherapy, is a rapidly developing field. The strategy of combining immunotherapies together has been under study for some time, but the large studies have not come out yet. I focused my talk on combining immunotherapy with chemotherapy, particularly in the frontline space. I limited my talk to the 2 large pieces of data that have been presented, but they are 2 very confusing studies. These are studies that have led to the FDA approval, which I argued might not be fully warranted with the current data.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication